Jammu, April 18: A scientific conclave and interactive session on Indian Pharmacopoeia (IP) 2026 was held at the CSIR-Indian Institute of Integrative Medicine on April 17, bringing together regulators, academic experts, and industry representatives to discuss advancements in drug standards and pharmaceutical quality, officials said.
The event was organised by the Indian Pharmacopoeia Commission in collaboration with the Council of Scientific and Industrial Research. The conclave focused on strengthening pharmacopoeial standards to ensure the quality, safety, and efficacy of medicines.
During the inaugural session, speakers highlighted the role of the Indian Pharmacopoeia in maintaining uniform drug standards across the country. They emphasised the need to continuously update regulatory frameworks in line with evolving scientific developments and global benchmarks.
Technical sessions during the conclave addressed key updates proposed under IP 2026, including the development and revision of drug monographs, strengthening impurity standards, and the adoption of advanced analytical methods. Discussions also covered regulatory perspectives, standardisation of phytopharmaceuticals, and improvements in microbiological and blood-related standards.
Officials said these measures are aimed at enhancing the robustness of pharmaceutical quality systems and ensuring that medicines meet established safety and efficacy requirements.
The interactive session provided a platform for stakeholders to deliberate on implementation challenges, industry preparedness, and alignment with international standards. Participants stressed the importance of collaboration between regulatory bodies, research institutions, and the pharmaceutical industry for effective adoption of updated standards.
Experts noted that evolving drug development practices and emerging healthcare needs require continuous refinement of pharmacopoeial guidelines. The conclave highlighted the need for sustained engagement among stakeholders to address these challenges.
The Indian Pharmacopoeia Commission reiterated its commitment to advancing pharmacopoeial standards through scientific innovation and stakeholder consultation. Officials said such initiatives are critical for strengthening public health safeguards and ensuring the availability of quality medicines in the country. (PIB)
Comments are closed.